What does absence of lymph node in resected specimen mean after neoadjuvant chemoradiation for rectal cancer

Won-Suk Lee1, Seok Ho Lee2, Jeong-Heum Baek1*, Woon Kee Lee1*, Jung Nam Lee1, Na Rae Kim3 and Yeon Ho Park1

Abstract
Background: The effect of insufficient node sampling in patients with rectal cancer managed by neoadjuvant chemoradiation followed by surgery has not been clearly determined. We evaluated the impact of insufficient sampling or even absence of lymph nodes in the specimen on survival in patients at high-risk (T3, T4 or node positive) for rectal cancer.

Methods: We conducted a single institution, retrospective analysis of all patients who underwent surgical rectal resection following neoadjuvant chemoradiation for treatment of mid to lower rectal cancer between 1997 and 2009. ypNX was defined as the absence of lymph nodes retrieved in the resected specimen.

Results: A total of 132 patients underwent resection for treatment of rectal cancer following neoadjuvant chemoradiation. Ninety four patients (71.2%) were considered as having node-negative disease, including ypNx and ypN0. In 38 patients (28.8%), the primary tumor was associated with regional lymph node metastases (ypNpos). The mean number of retrieved nodes per specimen was 14.2, respectively. The five-year overall survival from initial operation for the ypNx group was 100%, respectively. The estimated five-year overall survival for ypN0 and ypNpos was 84.0% and 60.3%, respectively (P =0.001). No significant differences in overall survival were observed between the ypNx and ypN0 group (P =0.302).

Conclusion: Absence of recovered LN in resected specimens after neoadjuvant chemoradiation was observed in 7.6% of specimens. Absence of LN should not be regarded as a risk factor for poor survival or as a sign of less radical surgery.

Keywords: Rectal neoplasm, Surgery, Neoadjuvant chemoradiation

Introduction
It is estimated that approximately 50 ~ 60% of rectal cancers are considered to be locally advanced tumors with clinical stage T3 or T4 or node positive disease, characterized by poor prognosis due to increased incidence of systemic and local recurrence and decreased long-term survival [1]. The preferred strategy for management of locally advanced mid to distal rectal cancer is multimodality treatment that includes radical surgery, chemotherapy, and radiation therapy. Radical surgery should be performed according to established surgical principles, which include en bloc resection of the tumor-bearing rectum and the adjacent lymphovascular pedicle, commonly referred to as total mesorectal excision [2].

The lymph node (LN) status remains one of the independent prognostic factors in rectal cancer. Patients without LN metastases have significantly better survival, compared to node positive patients, in the absence of distant metastasis. However, a minimum number of LNs retrieved from the resected specimen is prerequisite to ensuring both adequate nodal sampling and surgical radicality [3]. Several studies have demonstrated a significant survival benefit of patients with node negative disease with an increased number of recovered nodes...
Chemoradiation exerts effects not only on tumor down staging and rate of metastatic LN but also on the overall number of retrieved nodes [7,8]. The number of LNs assessed pathologically is a combination of the aggressiveness of the surgeon in resecting widely around the primary tumor and of the dedicated pathologist in searching the specimen for additional nodes. Inadequate retrieval of LNs is considered unacceptable for patients who have not undergone pretreatment and went straight to surgery. However, the effect of this finding in patients with rectal cancer managed by neoadjuvant chemoradiation followed by surgery has not yet been determined.

In an attempt to determine the impact of insufficient sampling (i.e. ypN ≤ 12) or even absence of lymph nodes in the specimen (i.e. ypNx) on survival in these patients, we evaluated a cohort of patients who enrolled in our neoadjuvant chemoradiation protocol for patients with high-risk (T3, T4 or node positive) rectal cancer.

**Patients and methods**

**Eligibility**

Between September 1997 and September 2009, 720 patients with rectal cancer underwent treatment at Gachon Medical Center. The inclusion criteria for the study were as follows: 1) lesion located no more than 10 cm from the anal verge; 2) clinical TNM stage II and III (T2-T4, or N positive and M0) on abdominopelvic computed tomography; 3) patients with histologically proven rectal carcinoma; 4) age ≥ 18 years; 5) patients who underwent preoperative chemoradiation; 6) mid (anal verge 6 cm to 10 cm) and lower (anal verge 1 cm to 5 cm) rectal cancer patients. Of the 720 patients screened for rectal resection, 132 patients fulfilled the inclusion criteria and were included in this retrospective analysis.

**Pretreatment staging**

Initial staging included complete physical examination, digital rectal examination, colonoscopy, serum CEA (carcino-embryonic antigen) abdominal and pelvic spiral CT scans, and endorectal ultrasonography or rectal magnetic resonance imaging in selected patient chest X-ray.

**Treatment**

All patients received two initial cycles of chemotherapy followed by pelvic radiation therapy plus chemotherapy. The concurrent chemotherapy was performed at the first and fifth week of radiation with bolus intravenous 5-fluorouracil 400 mg/m² and leucovorin 20 mg/m² for five days per week. All patients received external beam radiation therapy (median dose, 50.40 Gy; range 48.4 to 55.8 Gy), according the previously published techniques [9,10]. Using 6 to 10 Mv photons, a 3- or 4-field technique was used.

Surgery was attempted at 6–8 weeks after completion of neoadjuvant chemoradiotherapy. All patients underwent low anterior resection or abdominoperineal resection and total mesorectal excision (TME) according to the surgical technique described by Heald et al. [11] as well as high ligation inferior mesenteric artery and en bloc resection of any suspected adjacent organ invasion. Four cycles of postoperative adjuvant chemotherapy with 5-fluorouracil 500 mg/m² for five days was added.

**Staging**

Two pathologists performed meticulous dissection and retrieval of mesorectal lymph nodes. A rigorous search of the mesorectum was performed in order to identify as many lymph nodes as possible. Each lymph node was analyzed in its entirety in separate blocks. When fewer than 12 lymph nodes were found, an additional 24-hour surfixation in Bouin’s fluid was performed in order to facilitate recovery of residual lymph nodes. No clearing technique was performed. Patients were staged according to the American Joint Committee on Cancer recommendations [12]. ypNX was defined as the absence of lymph nodes recovered in the resected specimen.

**Surveillance**

Surveillance for recurrence following surgery was outlined as follows: physical examination, serum CEA, chest X-ray, and spiral abdominal CT scan were performed every six months for three years, and annually thereafter.

**Statistical methods**

The primary endpoint of the study was overall survival. Overall survival (OS) was estimated using the Kaplan-Meier method. OS was measured from the date of diagnosis to the date of death or the last follow-up visit. Survival rates were compared for statistical differences using log-rank analysis. Chi squared and ANOVA were used for categorical and numeral variables between groups. Multivariate analysis was performed using stepwise Cox proportional hazards regression modeling. P values less than .05 were considered statistically significant and all P values correspond to two-sided significance tests.

**Results**

**Patient characteristics**

There were 95 men and 37 women enrolled in the study. The median age of subjects was 59 years (39-77). The median follow up from primary surgery was 54.2 months (range, 12.1-128.5 months). Primary lesions were found above 6 cm or more from the anal verge in 82 patients (62.1%) and below 5 cm in 50 patients (37.9%) (Table 1).

The median interval time between completion of preoperative chemoradiation and surgery was 6.2 weeks (range, 4.4-8.6 weeks). Among the 132 patients, 52
(39.4%) underwent low anterior resections with or without protective ileostomy; 39 (29.5%) underwent ultralow low anterior resections with or without protective ileostomy; 22 (16.7%) underwent Hartmann’s procedure and 19 patients (14.3%) underwent abdominoperineal resections. A summary of patient characteristics is shown in Table 1. In this study, 92 patients (69.7%) underwent a sphincter saving operation without permanent colostomy.

A total of 94 patients (71.2%) were considered as having node-negative disease, including ypNx and ypN0. In 38 patients (28.8%), the primary tumor was associated with regional lymph node metastases (ypNpos). The mean number of retrieved nodes per specimen was 14.2, respectively. The rate of complete sterilization, i.e., staged ypTxN0 and ypTxNx, was 6.8% (nine patients). Of the 130 patients with clinical stage III, 92 patients (69.7%) (9 + 2 + 28 + 53 patients) were downstaged after chemoradiation (Table 2). All of the ypNx patients (n = 11) had clinically significant lymph node enlargement(s).

**Table 2 TNM downstaging in a series of 132 rectal cancer patients treated with preoperative chemoradiotherapy**

| CR | 0 | I | II | III | Total |
|----|---|---|----|-----|-------|
| cII* | 0 | 0 | 1 | 1 | 0 | 2 |
| cIII* | 9 | 2 | 28 | 53 | 38 | 130 |
| Total | 9 | 2 | 29 | 54 | 38 | 132 |

*Clinical stage II or stage III.

**Table 1 Patient characteristics (n = 132)**

| Variables | Number of patients | % |
|-----------|--------------------|---|
| Median age | 59.0(39-77) | |
| ≤ 60 | 61 | 46.2 |
| > 60 | 71 | 53.8 |
| Sex: M/F | 95:37 | |
| Primary tumor location | | |
| Mid | 109 | 47.0 |
| Lower | 23 | 53.0 |
| Pretreatment CEA, ng/mL* | | |
| Median | 5.32(0.1-83.3) | |
| ≤ 5.0 | 112 | 84.8 |
| > 5.0 | 20 | 15.2 |
| ypT stage | | |
| Tx | 9 | 6.8 |
| T1 | 1 | 0.8 |
| T2 | 29 | 22.0 |
| T3 | 92 | 69.7 |
| T4 | 1 | 0.8 |
| ypN stage | | |
| x | 11 | 8.3 |
| 0 | 83 | 62.9 |
| positive | 38 | 28.8 |
| Retrieved nodes | | |
| Mean | 14.2(0-31) | |
| Lymphovascular invasion | | |
| Positive | 30 | 77.3 |
| Negative | 102 | 22.7 |
| Perineural invasion | | |
| Positive | 13 | 9.8 |
| Negative | 119 | 90.2 |
| Cell differentiation | | |
| Well | 12 | 9.1 |
| Moderately | 104 | 78.8 |
| Poorly or mucinous | 16 | 12.1 |
| Body mass index | | |
| ≤ 22 | 39 | 29.5 |
| > 22 | 93 | 70.5 |

*CEA, carcinoembryonic antigen (normal range 0-7 ng/mL). Numbers in parenthesis indicate ranges.

**Lymph node status**
Pathologist A evaluated 74 patients and retrieved an average of 13 (range, 0-24) lymph nodes and Pathologist B evaluated 58 patients and retrieved 15 (range, 0-31) lymph nodes, respectively. There were 11 patients (8.3%) with absence of lymph nodes recovered in the resected specimen, i.e., ypNx (0 out of 0). The overall pathologic characteristics of ypT stage and ypN stage are shown in Table 3. In comparison of patients with ypNx and those with ypN0, no significant differences were observed in terms of gender, age, CEA, cell type, and body mass index. However, significantly lower risk of lymphovascular invasion was observed in the ypNx group, compared with the ypNpos group (P = 0.001) (Table 4).

**Risk factor analyses**
In univariate analyses, CEA greater than 5, primary node status, and lymphovascular invasion had a statistically significant adverse influence on survival (Table 5). Although the results of multivariate analysis are limited by the small number of patients, results of stepwise Cox
multivariate regression analysis revealed lymph node metastasis as a single independent prognostic factor affecting overall survival ($P = 0.029$; relative risk, 2.233; 95% Confidence Interval = 1.087-4.587).

**Disease recurrence and survival**
The overall recurrence rate was 18.3% (25 patients) and overall cancer-related mortality was 17.4% (23 patients). No recurrences were observed among the ypNx group. Comparison of recurrences and cancer-related deaths showed significant differences between the ypNx and ypN0 group ($P = 0.032$) (Table 6). Five-year overall survival for patients with ypNx group 100%. The estimated five-year overall survival for ypN0 and ypNpos was 84.0% and 60.3%, respectively (Figure 1). The estimated five-year disease free survival for ypN0 and ypNpos was 82.8% and 58.9%, respectively (Figure 2). No significant difference in overall survival was observed between the ypNx and ypN0 group ($P = 0.302$). However, the ypNpos group showed significantly worse five-year survival than the ypNx and ypN0 groups ($P = 0.002$).

**Discussion**
Neoadjuvant chemotherapy and radiation therapy for treatment of locally advanced rectal cancer is a widely accepted treatment before surgical operation. Although it was initially used to improve rates of sphincter preservation and to optimize patient tolerance, the ideal number of nodes for rectal cancer surgery has been an issue of controversy. Many studies have demonstrated that the number of lymph nodes involved with a tumor has a strong impact on outcome for patients treated for rectal cancer [3]. Indeed, the TNM staging system is based on whether one to three nodes are involved or four or

### Table 4 Clinicopathological characteristics of patients according to ypN status (n = 132)

| Parameter                        | ypNx,% | ypN0,% | ypNpos,% | P-value     | P-value, ypNx vs ypN0 |
|----------------------------------|--------|--------|----------|-------------|-----------------------|
| Number of patients               | 11(8.3)| 83(62.9)| 38(28.8) | 0.434       | 0.725                 |
| Mean age (yr) ± STD              | 66.9 ± 11.3 | 59.5 ± 8.80 | 58.5 ± 11.4 | 0.514          | 0.680                 |
| Primary tumor location           |        |        |          |             |                       |
| Mid                              | 11(100.0) | 70(84.3) | 28(73.7) |             |                       |
| Lower                            | 0(0.0)  | 13(15.7) | 10(26.3) |             |                       |
| Pretreatment CEA (ng/mL)         | 5.59 ± 5.08 | 4.02 ± 5.67 | 7.36 ± 17.7 | 0.229  | 0.926                 |
| Cell differentiation             |        |        |          |             |                       |
| Well                             | 0(0.0)  | 7(8.4)  | 5(13.2)  |             |                       |
| Moderate                         | 8(72.7) | 69(83.1) | 27(71.1) |             |                       |
| Poorly                           | 3(27.3) | 7(8.5)  | 6(15.7)  |             |                       |
| Perineural invasion              | 3(27.3) | 3(3.6)  | 7(18.4)  | 0.102       | 0.288                 |
| Lymphovascular invasion          | 3(27.3) | 9(10.8) | 18(47.4) | 0.001       | 0.435                 |
| Body mass index                  | 22.18 ± 1.57 | 23.39 ± 3.14 | 22.86 ± 2.61 | 0.723     | 0.091                 |
| Retrieved nodes                  | -       | 13.45 ± 7.59 | 17.9 ± 6.87 | 0.720     | 0.047                 |

CEA Carcinoembryonic antigen, STD Standard deviation.

### Table 5 Univariate predictors of adverse outcome (n = 132)

| Variables | 5-year survival,% | P-value |
|-----------|-------------------|---------|
| Age       |                   |         |
| ≤ 60      | 85.0              | 0.053   |
| > 60      | 77.0              |         |
| Primary tumor location |       |         |
| Mid       | 80.1              | 0.004   |
| Lower     | 70.7              |         |
| CEA, ng/mL* |            | 0.001   |
| ≤ 5.0      | 84.3              |         |
| > 5.0      | 45.2              |         |
| Pathologic N stage |      |         |
| ypNx       | 100               | 0.003   |
| ypN0       | 85.0              |         |
| ypNpos     | 60.3              |         |
| Lymphovascular invasion |      | 0.642   |
| Positive   | 70.8              |         |
| Negative   | 78.8              |         |
| Perineural invasion |     | 0.951   |
| Positive   | 75.0              |         |
| Negative   | 79.7              |         |
| Cell differentiation |     | 0.709   |
| Well       | 75.0              |         |
| Moderately poorly | 79.7 |         |
| Body mass index |    | 0.838   |
| ≤ 22      | 73.4              |         |
| > 22      | 77.1              |         |

CEA Carcinoembryonic antigen (normal range 0-7 ng/mL), N Number.
An apparent increase in the number of retrieved nodes in patients with N1 or N2 disease, when compared to N0 disease, has been reported [3,6]. Although there is no clear agreement on the absolute number of total retrieved nodes, [3,13-15] the American Joint Committee on Cancer (AJCC) has recommended at least 12 lymph nodes as the standard for adequate staging of colon and rectal disease [12,16]. The AJCC staging does not include an exception criteria for pretreated rectal cancer, which in fact may have several factors that interfere with lymph node retrieval after rectal cancer surgery. In addition, the impact of absence of lymph nodes in the resected specimen after radical surgery for treatment of mid to distal rectal cancer after neoadjuvant chemoradiation has not been clearly defined in terms of overall survival.

In this study, the mean number of lymph nodes recovered after neoadjuvant chemoradiation followed by radical surgery was 14.2 LN per specimen, whereas the rate of ypNx was 7.6%. Findings of this series showed a statistically significant higher number of nodes in node positive patients, compared with node negative patients. For example, Wong et al. [17] reported that a mean of 14 nodes was found in node negative patients, as compared with 20 nodes in node positive patients. Unlike the study reported by Gorog et al. [18] and Kuo et al. [19], in this study, body surface area did not affect the number of LN retrieved. The major weakness of this study is that the results are based on 11 patients with no recurrent disease after ypNx. The retrospective nature and small sample size might actually have affected statistical analysis.

In a population-based study, including 5000 patients with rectal cancer from the SEER (Surveillance, Epidemiology, and End Results) database, results of multivariate analysis showed that patients who underwent preoperative radiation had significantly fewer recovered nodes, as compared with patients treated by adjuvant therapy [20]. The main reason for more retrieved nodes in this study may have resulted from complete total mesorectal excision with high ligation of inferior mesenteric vessels; however, a more likely explanation is the pathologist’s determination to retrieve as many nodes as possible.

The clinical impact of decreased retrieval of LN after neoadjuvant chemoradiation has not yet been clearly

| Parameter          | ypNx | ypNO | ypNpos | P-value |
|--------------------|------|------|--------|---------|
| Recurrence         | 0    | 11   | 14     | 0.052   |
| Cancer related mortality | 0    | 10   | 13     | 0.002   |

Figure 1 Overall survival according to ypN status (n = 132) (p = 0.003).
defined. It is generally believed that examining a greater number of nodes increases the likelihood of proper staging and thus might benefit from adjuvant therapy. Is survival in the ypNx population worse than that in the ypN0 population? In our series, the answer is no. The ypNx group exhibited a tendency toward better overall survival than the ypN0 group. The ypNx group may reflect an increased sensitivity to chemoradiation, which ultimately results in downstaging, as suggested by Habr-Gama et al. [5]. In fact, some of patients with ypNx could have been node positive patients before neoadjuvant chemoradiation. The results of the current series should be interpreted with caution. Due to the retrospective nature of this study, the analysis of disease free survival, local recurrence free survival and overall survival lack significant variables having a major impact on the outcome. Based on our results, the authors of this study suggest that the current recommendation of minimum requirement for LN retrieved (i.e. more than 12 nodes) for proper staging in these subsets of patients may be inappropriate and that conduct of more larger studies comparing the therapeutic outcome of ypNx and ypN0 is definitely warranted.

A wide range of tumor responses after preoperative chemoradiation therapy have been reported [2,6,9,21,22]. The reason for this wide variability in tumor responses is unclear. The results of studies reporting predictive clinicopathologic factors of tumor response are controversial and patients in the ypNx group may be associated with increased sensitivity toward chemoradiation therapy, and, thus, toward better survival. Some molecular biomarkers and various enzymes that may predict tumor response to chemotherapy have been suggested [19,23-25]. Neoadjuvant chemoradiation therapy has played a critical role in improving resectability and downstaging tumors. A variety of neoadjuvant chemoradiation regimens and radiosensitizers should be investigated for improvement of tumor response after chemoradiation and further prediction of tumor response.

In conclusion, absence of recovered LN in a resected specimen after neoadjuvant chemoradiation is rare and was observed in 7.6% in this series. Patients with ypNx after neoadjuvant chemoradiation and radical surgery may not be considered as patients at high risk for development of recurrence.
Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
WSL provided the original idea and drafted the manuscript. SHL contributed in manuscript preparation. JHB contributed in the statistical analysis. WKL and JNL contributed in data collection and analysis. NRK contributed in pathologic reading of the data. YHP drafted the manuscript. WSL provided the concept and design of the study, WKL, SHL and JHB is responsible for data collection and analysis, WSL, YHP and NRK participated in the sequence alignment and drafted the manuscript. All authors read and approved the final manuscript.

Author details
1Department of Surgery, Gil Medical Center, School of Medicine, Gachon University, 1198 Guwol-dong, Namdong-gu, Incheon 405-760, Korea.
2Department of Pathology, Gil Medical Center, School of Medicine, Gachon University, 1198 Guwol-dong, Namdong-gu, Incheon 405-760, Korea.
3Department of Radiation Oncology Gil Medical Center, School of Medicine, Gachon University, 1198 Guwol-dong, Namdong-gu, Incheon 405-760, Korea.

References
1. Jessup JM, Stewart AK, Mendk HR: The national cancer data base report on patterns of care for adenocarcinoma of the rectum, 1985-95. Cancer 1998, 83(11):2408–2418.
2. Lee WS, Yun SH, Roh YN, Yun HR, Lee WY, Cho YB, Chun HK: Risk factors and clinical outcome for anastomotic leakage after total mesorectal excision for rectal cancer. World J Surg 2008, 32B(6):1124–1129.
3. Tepper EJ, O’Connell MJ, Niedzwiecki D, Hollis D, Compton C, Benson AB 3rd, Cummings B, Gunderson L, Macdonald JS, Mayer RJ: Impact of number of lymph nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 2001, 19(1):157–163.
4. Prandi M, Lionetto R, Bini A, Franchioni G, Accappio G, Anfossi A, Ballario E, Becchi G, Bonilauri S, Carobbi A, et al: Prognostic evaluation of stage B colorectal cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial. Ann Surg 2002, 235(4):458–463.
5. Habr-Gama A, Perez RP, Proscurshim I, Rawet V, Pereira DO, Sousa AH, Kiss D, Cecconeillo I: Absence of lymph nodes in the resected specimen after radical surgery for distal rectal cancer and neoadjuvant chemoradiation therapy: what does it mean? Dis Colon Rectum 2008, 51(3):277–283.
6. Kim MK, Baik SH, Seong JS, Kim H, Roh JK, Lee KY, Sohn SK, Cho CH: Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival. Ann Surg 2006, 244(6):1024–1030.
7. Wichmann MW, Muller C, Meyer G, Strauss T, Hornung HM, Lau-Werner U, Angele MK, Schillberg FW: Effect of preoperative radiochemotherapy on lymph node retrieval after resection of rectal cancer. Arch Surg 2002, 137(2):206–210.
8. Wijesuriya RE, Deen K, Hewawasamti J, Balawandas J, Perera M: Neoadjuvant therapy for rectal cancer down-stages the tumor but reduces lymph node harvest significantly. Surg Today 2005, 35(6):442–445.
9. Lee SH, Lee KC, Choi JH, Oh JH, Baik JH, Park SH, Shin DB: Chemoradiotherapy followed by surgery in rectal cancer: improved local control using a moderately high pelvic radiation dose. Jpn J Clin Oncol 2008, 38(2):112–121.
10. Medich D, McGinity J, Parda D, Karlovits S, Davis C, Causht J, Lembersky B: Preoperative chemoradiotherapy and radical surgery for locally advanced distal rectal adenocarcinoma: pathologic findings and clinical implications. Dis Colon Rectum 2001, 44(8):1123–1128.
11. Heald RJ, Husband EM, Ryall RD: The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? Br J Surg 1982, 69(10):613–616.
12. Greene FL, Page DL, Fleming ID, et al: AJCC cancer staging manual. 6th edition. New York: Springer-Verlag; 2002.
13. Scabini S, Ferrando V: Number of lymph nodes after neoadjuvant therapy for rectal cancer: How many are needed? World J Gastroenterol 2012, 4(2):32–35.
14. Perez RD, Habr-Gama A, Nishida Arazawa ST, Rawet V, Coelho Siqueira SA, Kiss DR, Gama-Rodrigues JI: Lymph node micrometastasis in stage II distal rectal cancer following neoadjuvant chemoradiation therapy. Int J Colorectal Dis 2005, 20(4):434–439.
15. Hughes R, Glynn-Rones J, Grainger J, Richman P, Makris A, Harrison M, Ashford R, Harrison RA, Livingstone J, McDonald PJ, et al: Can pathological complete response in the primary tumour following pre-operative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for sterilisation of pelvic lymph nodes, a low risk of local recurrence and the appropriateness of local excision? Int J Colorectal Dis 2006, 21(1):11–17.
16. Edge SB, Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010, 17(6):1471–1474.
17. Wong JH, Severino R, Honnebrew MB, Tom P, Nakisi T: Number of nodes examined and staging accuracy in colorectal carcinoma. J Clin Oncol 1999, 17(9):2986–2990.
18. Gorog D, Nagy P, Peter A, Perner F: Influence of obesity on lymph node recovery from rectal resection specimens. Pathol Oncol Res 2003, 9(3):180–183.
19. Ruo LJ, Chiou JF, Tai CJ, Chang CC, Kung CH, Lin SE, Hung CS, Wang W, Tam KW, Lee HC, et al: Can we predict pathologic complete response before surgery for locally advanced rectal cancer treated with preoperative chemoradiation therapy? Int J Colorectal Dis 2012, 27(3):613–621.
20. Baxter NN, Vining DJ, Rothenberger DA, Morris AM, Jessurun J, Vining BA: Lymph node evaluation in colorectal cancer patients: a population-based study. J Natl Cancer Inst 2005, 97(3):219–225.
21. Ahmad NR, Nagle D: Long-term results of preoperative radiation therapy alone for stage T3 and T4 rectal cancer. Br J Surg 1997, 84(10):1445–1448.
22. Minsky BD, Cohen AM, Kemeny N, Enker WE, Kelsen DP, Reichman B, Saltz L, Sigurdsson ER, Frankel J: Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach. J Clin Oncol 1992, 10(8):1218–1224.
23. Fu CG, Tomimagda N, Nagawa H, Nita ME, Masaki T, Ishimaru G, Higuchi Y, Tsueta T, Muto T: Role of p53 and p21/WAF1 detection in patient selection for preoperative radiotherapy in rectal cancer patients. Dis Colon Rectum 1998, 41(11):68–74.
24. Palazzo JP, Kafka NJ, Grasso L, Chakrani F, Hanau C, Cuesta KH, Mercer WE: The role of p53, p21/WAF1/CIP1, and bcl-2 in radioresistant colorectal carcinoma. Hum Pathol 1997, 28(10):1189–1195.
25. Villanueva E, Okruzhnov Y, Dominguez MA, Garcia-Fencillas J, Atzovic L, Martinez E, Illarramendi JJ, Arias F, Martinez Monge R, Salgado E, et al: Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001, 19(22):1779–1786.